Hypertension - Time to move on

Lancet

Volumn 365, Issue 9464, 2005, Pages 1108-1109

  MacMahon, S ^a,c   Neal, B ^a   Rodgers, A ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DECISION MAKING; DISEASE ASSOCIATION; DRUG MARKETING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HYPERTENSION; MEDICAL SOCIETY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 15244360675     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)74236-7     Document Type: Article

References (17)

1. AV Chobanian, GL Bakris, HR Black The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 report JAMA 289 2003 2560 2572
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
3. World Health Organization, International Society of Hypertension writing group 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension J Hypertens 21 2003 1983 1992
4. B Williams, NR Poulter, MJ Brown British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary BMJ 328 2004 634 640
5. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data from one million adults in 61 prospective studies Lancet 360 2002 1903 1913
6. CM Lawes, A Rodgers, DA Bennett Blood pressure and cardiovascular diseases in the Asia Pacific region J Hypertens 21 2003 707 716
7. S MacMahon, A Rodgers The epidemiological association between blood pressure and stroke: implications for primary and secondary prevention Hypertens Res 17 1994 23 32
8. World Health Organization World Health Report 2002: reducing risks, promoting healthy life 2002 World Health Organization Geneva
9. G Rose Sick individuals and sick populations Int J Epidemiol 30 2001 427 432
10. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
11. S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
12. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
13. R Collins, R Peto, S MacMahon Blood pressure, stroke, and coronary heart disease - part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context Lancet 335 1990 827 838
14. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
15. New Zealand Guidelines Group Guidelines for the Detection and Management of Cardiovascular Disease 2003 New Zealand Guidelines Group Wellington http://www.nzgg.org.nz (accessed Sept 14, 2004)
16. M Harrington, P Kincaid-Smith, J McMichael Results of treatment in malignant hypertension: a seven-year experience in 94 cases BMJ 2 1959 969 980
17. Reuters Business Insight Healthcare The cardiovascular market outlook to 2008 2003 Datamonitor PLC London